Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD), First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy ofmEphA4-Fc in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis (ALS)

Next Previous
Trial Profile

A Phase 1, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD), First-In-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy ofmEphA4-Fc in Healthy Volunteers and Patients with Amyotrophic Lateral Sclerosis (ALS)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 15 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs MEphA4-Fc (Primary)
  • Indications Amyotrophic lateral sclerosis
  • Focus Adverse reactions; First in man; Pharmacokinetics
  • Sponsors NuNerve

Most Recent Events

  • 15 Apr 2022 Planned End Date changed from 5 Oct 2021 to 26 Oct 2022.
  • 15 Apr 2022 Status changed from recruiting to active, no longer recruiting.
  • 10 May 2021 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top